BackOncolytics Biotech Overview

Oncolytics Biotech Receivables

Oncolytics Biotech's receivables is $1.2M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.21M
1586.11% YoYΔ $1.14M vs prior year quarter

Peer trimmed avg / median

Loading

Oncolytics Biotech Receivables History

Loading

Oncolytics Biotech vs. peers: Receivables Comparison

Loading

Oncolytics Biotech Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Oncolytics Biotech (ONCY) FAQ

As of the most recent data (June 2026), ONCY shows a receivables of $1.2M. That compares with $72K in the prior-year period — up 1586.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ONCY's receivables is now $1.2M (was $72K) — a 1586.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Oncolytics Biotech is outperforming or lagging.

Tracking ONCY's receivables over time shows whether Oncolytics Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2M That compares with $72K in the prior-year period — up 1586.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Oncolytics Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.2M) with ownership activity and broader fundamentals.

Oncolytics Biotech's receivables is $1.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.